Patents by Inventor Matthew Ernest Welsch

Matthew Ernest Welsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD16A BINDING AGENTS AND USES THEREOF
    Publication number: 20240051966
    Abstract: Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
    Type: Application
    Filed: November 18, 2022
    Publication date: February 15, 2024
    Inventors: Anna BUNIN, Lawrence G. IBEN, Douglas MANION, David Adam SPIEGEL, Matthew Ernest WELSCH
  • DIRECTED CONJUGATION TECHNOLOGIES
    Publication number: 20230128688
    Abstract: Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.
    Type: Application
    Filed: November 18, 2020
    Publication date: April 27, 2023
    Inventors: Luca RASTELLI, David Adam SPIEGEL, Matthew Ernest WELSCH, Tetyana BERBASOVA, Michael C. CUKAN, Lawrence Gerald IBEN, Ada Margaret VAILL, Anna BUNIN, Christian Marcel VIDAL, Enrique ALVAREZ
  • CD16A binding agents and uses thereof
    Patent number: 11572370
    Abstract: Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: February 7, 2023
    Assignee: BIOHAVEN THERAPEUTICS LTD.
    Inventors: Anna Bunin, Lawrence G. Iben, Douglas Manion, David Adam Spiegel, Matthew Ernest Welsch
  • CD38-BINDING AGENTS AND USES THEREOF
    Publication number: 20230028880
    Abstract: Among other things, the present disclosure provides compounds comprising antibody binding moieties and CD38-binding targeting moieties. In some embodiments, provided compounds recruit various types of antibodies to diseased cells such as cancer cells, and induce immune activities to kill such cells. Provided technologies are useful for treating various diseases including cancer.
    Type: Application
    Filed: June 24, 2020
    Publication date: January 26, 2023
    Inventors: Luca RASTELLI, Matthew Ernest WELSCH, Anna BUNIN, Ann Marie K. ROSSI, Tetyana BERBASOVA
  • CD16A BINDING AGENTS AND USES THEREOF
    Publication number: 20220356191
    Abstract: Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
    Type: Application
    Filed: January 8, 2019
    Publication date: November 10, 2022
    Inventors: Anna Bunin, Lawrence G. Iben, Douglas Manion, David Adam Spiegel, Matthew Ernest Welsch
  • UNIVERSAL ABT COMPOUNDS AND USES THEREOF
    Publication number: 20200390895
    Abstract: Among other things, the present disclosure provides compounds comprising universal antibody binding moieties and targeting moieties. In some embodiments, provided compounds recruit various types of antibodies to diseased cells such as cancer cells, and induce immune activities to kill such cells. Provided technologies are useful for treating various diseases including cancer.
    Type: Application
    Filed: July 26, 2018
    Publication date: December 17, 2020
    Inventors: David Adam Spiegel, Matthew Ernest Welsch
  • Antibody-recruiting molecules for the treatment of cancer
    Patent number: 10780084
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 22, 2020
    Assignees: YALE UNIVERSITY, KLEO PHARMACEUTICALS, INC.
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch
  • ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER
    Publication number: 20190192497
    Abstract: The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic and other cancers where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 27, 2019
    Inventors: David Spiegel, H. Marie Loughran, Jeffrey C. Pelletier, Allen B. Reitz, Matthew Ernest Welsch